隶属于 hmh hospitals corp, inc.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Hackensack Meridian Health opened a new cancer center at JFK University Medical Center in Edison, NJ in May 2025, bringing together multiple oncology specialties under one roof. - The facility's design promotes real-time collaboration among medical oncologists, surgeons, radiation oncologists, and support services, enabling faster clinical decision-making for cancer patients. - Leadership emphasizes that strong network infrastructure and centralized resources, including financial counseling and insurance navigation, help reduce physician burnout while improving patient care.
- RWJBarnabas Health and Rutgers Cancer Institute have opened the Jack & Sheryl Morris Cancer Center in New Brunswick, marking New Jersey's first freestanding comprehensive cancer hospital. - The 12-story facility features 96 inpatient beds, 88 infusion bays, dedicated surgical floors, and research infrastructure, eliminating the need for New Jersey residents to travel to New York or Philadelphia for specialized cancer treatment. - Hackensack Meridian Health has also expanded its John Theurer Cancer Center in Edison with a $14 million renovation, doubling infusion capacity and enhancing surgical, medical, and radiation oncology services.
- A phase I/II trial (CA057-003) evaluating mezigdomide-based combinations in relapsed or refractory multiple myeloma shows promising results, according to findings presented at the American Society of Hematology annual meeting. - Mezigdomide, a newer derivative of thalidomide, maximizes the qualities of thalidomide derivatives, exhibiting both direct tumoricidal effects and modulating the immune response to tumors. - The combinations studied were well-tolerated, with no unexpected toxicities, and demonstrated durable responses in a patient population where such outcomes were not highly anticipated. - The trial suggests that mezigdomide-based combinations could offer a valuable treatment option for patients with relapsed or refractory multiple myeloma, improving outcomes without unacceptable toxicities.
- A 33-year-old patient with acute myeloid leukemia (AML) achieved remission through a clinical trial using IDHIFA, an oral medication targeting the IDH2 mutation. - The patient, who initially underwent intensive remission induction therapy with chemotherapy, opted for the IDHIFA trial as an alternative to a bone marrow transplant. - IDHIFA works by turning off the mutated IDH2 gene, restoring normal cell function and offering a targeted approach to treating AML in patients with this specific mutation. - The patient experienced minimal side effects and has returned to work and normal activities, highlighting the potential of targeted gene therapy in leukemia treatment.
